Methods for Determining Probability of an Adverse or Favorable Reaction to a Niacin Receptor Agonist

• Main Authors: MACIEJEWSKI-LENOIR DOMINIQUE, KANEMITSU-PARKS MARTHA, RICHMAN JEREMY G, CONNOLLY DANIEL T, LIAW CHEN W
• Format: Patent
• Language: English
• Published: 07.05.2009
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

The present invention relates generally to a GPR109A niacin receptor. The present invention relates more particularly to assessing a GPR109A polymorphism in an individual, wherein the GPR109A polymorphism is indicative of the subject's risk for an adverse reaction to the administration of a GPR109A receptor agonist, wherein the adverse reaction is associated with stimulation of MAP kinase activity by the GPR109A receptor agonist. More specifically, the present invention relates to assessing a GPR109A polymorphism in an individual and determining the level of risk for the subject for experiencing an adverse reaction, wherein the subject's GPR109A zygosity is predictive of the risk for a cutaneous flushing response that can be experienced following administration of a GPR109A receptor agonist.